Boston Common Asset Management LLC Has $10.77 Million Position in Gilead Sciences, Inc. $GILD

Boston Common Asset Management LLC lessened its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 77,243 shares of the biopharmaceutical company’s stock after selling 7,238 shares during the quarter. Boston Common Asset Management LLC’s holdings in Gilead Sciences were worth $10,765,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Planning Alternatives Ltd. ADV acquired a new stake in shares of Gilead Sciences in the 1st quarter worth about $216,000. Broderick Brian C bought a new position in Gilead Sciences in the 1st quarter valued at about $461,000. Nelson Capital Management LLC acquired a new position in Gilead Sciences during the 1st quarter valued at about $408,000. Decker Wealth Management LLC acquired a new position in Gilead Sciences during the 1st quarter valued at about $394,000. Finally, SEB Asset Management AB bought a new stake in Gilead Sciences during the 1st quarter worth approximately $171,843,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on GILD. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price objective for the company in a research note on Wednesday, May 20th. Rothschild & Co Redburn cut their target price on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Daiwa Securities Group lowered their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Finally, The Goldman Sachs Group raised their price objective on Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a research note on Friday, April 17th. Twenty-six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $159.04.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $134.28 on Monday. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The firm has a market cap of $166.72 billion, a price-to-earnings ratio of 18.29 and a beta of 0.32. Gilead Sciences, Inc. has a 52 week low of $107.75 and a 52 week high of $157.29. The firm has a 50-day moving average price of $129.73 and a two-hundred day moving average price of $135.30.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter last year, the firm earned $1.81 EPS. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts expect that Gilead Sciences, Inc. will post -0.77 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 29th. Investors of record on Monday, June 15th were issued a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date was Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is 44.69%.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total transaction of $1,894,350.00. Following the completion of the sale, the chief executive officer directly owned 607,133 shares of the company’s stock, valued at $76,674,826.57. This trade represents a 2.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $123.92, for a total value of $371,760.00. Following the sale, the insider directly owned 124,234 shares of the company’s stock, valued at approximately $15,395,077.28. This represents a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 77,000 shares of company stock worth $9,978,740. 0.30% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.